Why One Fund Made a $23 Million Bet on This Addiction-Treatment Stock Amid a Staggering Rally

Claret Asset Management disclosed a new 707,267-share position in Indivior, valued at $21.56 million at quarter end and estimated at $23.36 million based on quarterly average pricing. The stake represented about 2.6%-2.8% of Claret’s 13F AUM, signaling meaningful conviction in the name. Indivior’s latest quarter was strong, with revenue up 19% year over year to $317 million, Sublocade sales up 32% to $232 million, and adjusted EBITDA up 112% to a record $164 million, alongside continued share repurchases and an increased full-year outlook.

Analysis

The key signal is not the new position itself, but that an institutional buyer chose to size into INDV after a major run, which suggests the market is still underestimating the durability of cash conversion rather than just chasing momentum. The combination of buybacks, balance-sheet cleanup, and a scaling flagship product creates a cleaner equity story: fewer shares outstanding can mechanically amplify per-share growth even if top-line growth moderates. That matters because in specialty pharma, once the market stops discounting “single-product fragility,” valuation can rerate quickly on sustained EBITDA delivery.

Second-order beneficiaries are the capital allocators around INDV, not just INDV itself. If management keeps executing on repurchases while debt costs fall, the equity can compound faster than fundamentals alone would imply, which can force short sellers and event-driven holders to cover on each earnings beat. The flip side is that the stock likely becomes more sensitive to any moderation in prescription growth because expectations will now be anchored to continued acceleration rather than mere stability.

The main risk is timeline mismatch: the bullish thesis is months-long, but the stock may already be pricing in a large portion of the near-term operating improvement. Any regulatory noise, payer pushback, or signs that prescription momentum is normalizing could compress the multiple before the buyback benefit has time to accrue. Consensus may be missing that the biggest upside driver is not product growth alone, but the interaction of growth plus shrinking float plus improving leverage metrics.

Contrarian angle: after a 12-month tripling, the market may still be treating INDV like a high-beta biotech despite it looking more like a cash-generative, capital-return story. If that reclassification continues, the next leg is likely less about absolute revenue surprises and more about FCF yield and per-share earnings revisions. That favors owning the name through catalysts, but not blindly after strength.

Key Decisions for Investors

• Go long INDV on pullbacks rather than breakouts; use a 4-8 week entry window and size for a 15-20% upside / 10% downside setup if the next quarter confirms buyback support and recurring cash generation.
• Pair trade: long INDV / short a basket of lower-quality specialty pharma names with weaker cash generation over a 1-2 quarter horizon; the spread should widen if markets continue rewarding self-funding models.
• Buy INDV call spreads 3-6 months out to express continued rerating while capping downside; target a structure that pays off if the market assigns a higher FCF multiple, not just if the stock grinds higher.
• For existing holders, trim 20-30% into post-earnings strength and keep the balance for the next catalyst; the risk/reward worsens if the stock re-rates ahead of confirmation on operating momentum.
• Monitor for any slowdown in prescription growth or payer commentary; if those metrics soften, reduce exposure quickly because the stock’s biggest risk is multiple compression, not near-term earnings miss.